| Active substance |
Mazdutide |
| Also known as |
LY3298176 |
| Blood pressure |
May reduce blood pressure |
| Chemical name |
Tirzepatide |
| Dosage (medical) |
Typically started at 2.5 mg once weekly, can be increased to 5 mg, 10 mg, or 15 mg once weekly depending on response and tolerability |
| Dosage (sports) |
Not applicable as it is not used for performance enhancement |
| Effects |
Improves glycemic control, promotes weight loss |
| FORM |
1 vial x 10 mg |
| Formula |
C225H348N48O68 |
| Half-life |
Approximately 5 days |
| Hepatotoxicity |
No significant hepatotoxicity reported |
| Lab Test |
Monitoring blood glucose levels and HbA1c |
| Main action |
Lowers blood glucose levels |
| Side effects |
Nausea, diarrhea, decreased appetite, vomiting, constipation |
| Storage conditions |
Store in a refrigerator at 2В°C to 8В°C (36В°F to 46В°F), protect from light |
| Substance class |
Glucagon-like peptide-1 (GLP-1) receptor agonists |
| Trade name |
Mounjaro |
| Use in sports |
None, not used for performance enhancement |
| Manufacturer |
Dragon Pharma |
